Alca Med SRL
0.5 FTEAlca Med reported total assets of 290,279 € at the end of the 2025 financial year (annual accounts filed with the NBB on 09 Oct 2026), with 0.5 full-time equivalent.
The score of Alca Med shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +36 % Total assets -6 % Headcount (avg FTE) -50 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Alca Med's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 09 Oct 2026
- Year ended 31 Dec 2024filed on 26 Sep 2025
- Year ended 31 Dec 2023filed on 17 Oct 2024
- Year ended 31 Dec 2022filed on 09 Oct 2023
Alca Med's financial analysis
- Solvency12.3%sector median: 68.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Alca Med
Alca Med's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0777.544.080
- VAT number
- BE0777544080
- Peppol
- Registered · 0208:0777544080 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Nov 2021
- Registered office
- 1180 Uccle
- Size
- Micro · 0.5 FTE
- Latest accounts
- 2025 · filed on 09 Oct 2026
- Activity
- General medical practice activities (NACE 86210)
Alca Med (SRL) has been based in Uccle since 2021, active in: general medical practice activities. For 2025, it reports a net loss of 83,676 € and equity of 35,636 €; its revenue is not published. With 0.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 12.3%, below the median of its sector (68.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Alca Med
Companies in the same business, of comparable size and area, outside its group.
- Dr Van Osta David General medical practice activities Etterbeek · balance sheet 109,268 €
- Dokter Arlette de Lombaert General medical practice activities Herzele · balance sheet 735,878 €
- Dr. Eeckhout General medical practice activities Éghezée · balance sheet €1.85m
- Docteur Sophie Rousseau General medical practice activities Wavre · balance sheet 251,118 €
- Bonte Pieter , huisarts General medical practice activities Merelbeke-Melle · balance sheet 243,194 €
- Amandine Hester Médecine générale General medical practice activities Gembloux · balance sheet 221,249 €
- Cabinet Medical Docteur Boncire General medical practice activities Jemeppe-sur-Sambre · balance sheet 205,501 €
- Dr. Erik Peeters General medical practice activities Antwerp · balance sheet 470,286 €
Frequently asked questions about Alca Med
What is the revenue of Alca Med?
Alca Med files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Alca Med?
In Belgium, the VAT number is the company number prefixed with BE: BE0777544080 for Alca Med, if the company is VAT-registered. Its company number (CBE) is 0777.544.080.
Where is the registered office of Alca Med?
According to the CBE register, the registered office of Alca Med is in 1180 Uccle.
What is the equity of Alca Med?
At the close of the 2025 financial year, the equity of Alca Med amounts to 35,636 €, a solvency of 12.3% of total assets.
How many people work at Alca Med?
0.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Alca Med?
The register lists 1 active mandates at Alca Med. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Alca Med
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →